BEIJING/HONG KONG (Reuters) – Chinese medical device company Shenzhen Mindray Bio-Medical Electronics said it planned a 6.65 billion yuan ($927 million) deal to gain control of APT Medical to expand in cardiovascular disease-related businesses. A wholly owned unit of Mindray will buy a 21.12% stake in APT Medical from current shareholders, including funds linked to venture investment firm Qiming Venture, for 6.65 billion yuan, Mindray said on Sunday. The Mindray unit will become the controlling shareholder of APT Medical after the transaction, according to a Mindray filing to the Shenzhen stoc…